Apollomics Announces The First Approval Of Vebreltinib For MET Exon 14 Skip Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Apollomics Inc. announced that its Chinese partner, Avistone Biotechnology, received approval from the NMPA to commercialize vebreltinib for MET exon 14 skipping NSCLC in China. Apollomics is in discussions with the FDA for a New Drug Application in the U.S. based on clinical data from the SPARTA trial and Avistone's KUNPENG trial. NSCLC, which accounts for 85% of lung cancer cases, has limited treatment options for patients with MET exon 14 skipping mutations. Apollomics retains rights to vebreltinib outside China, Hong Kong, and Macau.
November 16, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apollomics Inc. has achieved a significant milestone with its partner Avistone receiving NMPA approval for vebreltinib in China, and is now pursuing FDA approval in the U.S. for the same indication.
The approval of vebreltinib in China is a positive development for Apollomics, indicating progress in its pipeline and potential for revenue growth in the Chinese market. The ongoing discussions with the FDA suggest that the company is actively working towards expanding its market presence in the U.S. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100